TrialNature aging2026

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.

M H Werner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.